Objective To determine the validity of adjusted indirect comparisons by using data from published meta-analyses of randomised trials. Design Direct comparison of different interventions in randomised ...
Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor ...
Zanubrutinib showed superior PFS and OS compared to acalabrutinib in R/R MCL, with HRs of 0.57 and 0.43, respectively. The STC approach was used due to the lack of head-to-head trials, providing ...
Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). Results from a first-in-human phase I study of ...
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis ...
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results